Zura Bio Ltd ZURA
Zura Bio Ltd (Nasdaq: ZURA) is an immunology/inflammation drug developer. Its lead program, tibulizumab (ZB-106), is in Phase 2 for Hidradenitis suppurativa (TibuSHIELD) and early diffuse cutaneous systemic sclerosis (TibuSURE). Its next catalyst on record is tibulizumab (HS): TibuSHIELD Phase 2 topline results (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: tibulizumab (HS) — TibuSHIELD Phase 2 topline results (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| tibulizumab (ZB-106) | Hidradenitis suppurativa (TibuSHIELD Phase 2, enrollment complete, n=247) | antibody | Phase 2 |
| tibulizumab (ZB-106) | Early diffuse cutaneous systemic sclerosis (TibuSURE Phase 2, enrollment complete, n=91) | antibody | Phase 2 |
| crebankitug (ZB-168) | Anti-IL-7Ralpha antibody; indications under assessment (prior Phase 1/1b by third parties) | antibody | Phase 1 |
| torudokimab (ZB-880) | Anti-IL-33 antibody; no current development plan (prior clinical studies before in-licensing) | antibody | Phase 1 |
| tibulizumab (ZB-106) | Polymyalgia rheumatica (Phase 2 planned) | antibody | Pre-clinical |
Recent results and decisions
- Aug 11, 2026completed enrollment TibuSHIELD Phase 2 completed enrollment with 247 participants randomized, above the 225 target.
The Phase 2 clinical study evaluating tibulizumab in adults with hidradenitis suppurativa (HS) has completed and exceeded enrollment, with 247 participants.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.